ESK-001-022
12 evidence topics · 2 sources
Objective
Brief summary in the ClinicalTrials.gov record
Location and study date
Study start and completion dates in the ClinicalTrials.gov record
“Study Start (Actual) 2025-04-29” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2026-03-24” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2026-03-24” (opens the source at this quote in a new tab)
“First Posted 2025-05-01” (opens the source at this quote in a new tab)
Completion dates estimated at registration, April 2025, superseded in May 2026
Sites in California, Florida, and Tennessee in the ClinicalTrials.gov record
| Site | Quoted record |
|---|---|
| California | “Lake Forest, California, United States, 92630” |
| Florida | “Miami Lakes, Florida, United States, 33104” |
| Florida | “Orlando, Florida, United States, 32809” |
| Tennessee | “Knoxville, Tennessee, United States, 37920” |
Recruitment and results status in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2026-05-12” |
Study design
Official title and design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Other study ID numbers | “ESK-001-022” |
| Conditions | “Hepatic Impairment” |
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |
Eligibility criteria
Key inclusion and exclusion criteria in the ClinicalTrials.gov record
Treatment
Arms and interventions in the ClinicalTrials.gov record
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Primary and secondary outcome measures in the ClinicalTrials.gov record
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Enrollment estimated at registration, April 2025, superseded in May 2026
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- The hepatic impairment study has no posted results, and the report holds no published results; its ClinicalTrials.gov record reads “No Results Posted”.
- The design is open-label and non-randomized, with one dose of ESK-001 of unstated strength and a 48-hour outcome time frame.
- Actual enrollment was 32 participants, against 48 estimated at registration and a planned structure of up to 24 healthy volunteers and 8 participants each with mild, moderate, and severe hepatic impairment; the number enrolled in each group is not reported.